Nurix Q2 net loss narrows to $24.3M ($0.45/sh) on $30.7M revenue; Gilead pays $20M for IRAK4 license

Nurix Therapeutics, Inc.

2023-Q2 EPS reported -$1.20 revenue$43,361,000

Net loss of $24.3M ($0.45 EPS) vs $45.4M ($1.01 EPS) in prior year; revenue $30.7M vs $11.4M.
Cash and marketable securities $308.6M as of May 31, 2023, down from $325.6M on Feb 28, 2023.
Gilead exercised option on NX-0479 (IRAK4 degrader) for $20M; up to $425M in milestones + royalties.
Phase 1b expansion started for NX-2127 in DLBCL and MCL; Phase 1a data for NX-5948 expected H2 2023.
NX-2127 and NX-5948 preclinical data showed potent activity against BTKi resistance mutations at AACR and ICML.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Nurix Therapeutics, Inc. reported the fiscal quarter ended May 31, 2023 results: revenue $30.7 million.

Period: the fiscal quarter ended May 31, 2023
Revenue: $30.7 million
Result: reported results

Exact text from the filing

Revenue for the three months ended May 31, 2023, was $30.7 million compared to $11.4 million for the three months ended May 31, 2022.

View on SEC.gov

Browse all earnings releases →

Nurix Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001549595-23-000039

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.